China is winning the first mile of drug innovation

WASHINGTON EXAMINER

The next breakthrough therapy may still be marketed in New York or Basel. But increasingly, it is being born in Shanghai.

China’s pharmaceutical industry has moved beyond imitation into something more consequential: early-stage innovation at scale. The clearest signal isn’t manufacturing output or even late-stage approvals. It’s what’s happening at the very front of the pipeline, Phase 1 and Phase 2 clinical trials, where scientific ideas first become viable medicines.

By that measure, China is no longer catching up. It is nearing parity with the U.S. and is gaining ground.

CRITICAL VULNERABILITY IN DRUG SUPPLY CHAIN PUTS US AT CHINA’S MERCY

Chinese companies now initiate roughly 30% of global clinical trials for innovative drugs, up from barely 5% a decade ago and approaching the U.S. share in the low 30s, according to industry estimates. A generation ago, China was largely absent from early-stage drug discovery. Today, it is one of the primary launch points.

The pipeline behind those trials is expanding even faster. Since 2020, the number of innovative drug candidates in development in China has surged by more than 200%, more than twice the pace of growth in the U.S., based on market analyses. This isn’t incremental progress — it’s a structural shift in where global pharmaceutical innovation originates.

The reasons are straightforward. China has built a system optimized for speed and cost — two variables that define early-stage drug development economics.

Read more here.